Selecting Multitarget Peptides for Alzheimer's Disease.

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) is a complex, multifactorial neurodegenerative disorder characterized by progressive cognitive decline.
• Current therapeutic strategies often target single pathways, limiting efficacy against the multifaceted nature of AD.
• Multitarget drug development offers a promising approach to address the complex pathogenesis of Alzheimer's disease.

Purpose of the Study:

• To identify and select a multitarget peptide candidate for Alzheimer's disease treatment.
• To evaluate peptide variants derived from cathepsin G for their potential to inhibit key AD-related molecular targets.
• To find a lead peptide with inherent multitarget activity for impacting cognitive decline.

Main Methods:

• Screened eight peptide candidates derived from cathepsin G.
• Assessed inhibition and reversion of amyloid beta (Aβ) oligomers using ELISA.
• Quantified peptide binding to receptor for advanced glycation end-products (RAGE), Toll-like receptor 4 (TLR4), and S100A9 via ELISA.
• Evaluated protection against Aβ oligomer-induced neuronal cell death using trypan blue assay.
• Measured inhibition of TLR4 activation by S100A9 in a reporter cell line.

Main Results:

• A 27-mer lead peptide was selected, demonstrating efficacy across all four screening criteria.
• The selected peptide effectively inhibited and reversed amyloid beta oligomers.
• The peptide exhibited direct binding to RAGE, TLR4, and S100A9.
• It provided protection against Aβ oligomer-induced neuronal cell death and inhibited TLR4 activation.

Conclusions:

• A novel 27-mer peptide was identified as a promising multitarget therapeutic candidate for Alzheimer's disease.
• This lead peptide possesses inherent multitarget activity, addressing both neuroinflammation and neurodegeneration.
• The peptide is expected to significantly impact cognitive decline in Alzheimer's disease models by targeting critical pathological pathways.